Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study
- Author
- KARAMPEAZIS, Athanasios1 ; VOUTSINA, Alexandra2 ; AGELAKI, Sofia2 3 ; VAMVAKAS, Lambros3 ; SAMONIS, George10 ; MAVROUDIS, Dimitris2 3 ; GEORGOULIAS, Vassilis2 3 ; SOUGLAKOS, John2 3 ; KENTEPOZIDIS, Nikos4 ; GIASSAS, Stelios5 ; CHRISTOFILLAKIS, Charalambos6 ; KOTSAKIS, Athanasios2 3 ; PAPAKOTOULAS, Pavlos7 ; RAPTI, Ageliki8 ; AGELIDOU, Maria9
[1] Medical Oncology Unit, 417 NIMTS Veterans Hospital, Athens, Greece
[2] Laboratory of Tumor Cell Biology, University of Crete, Heraklion, Crete, Greece
[3] Department of Medical Oncology, University General Hospital of Heraklion, Heraklion, Crete, Greece
[4] Department of Medical Oncology, 251 Air Force Hospital, Athens, Greece
[5] Department of Medical Oncology, IASO General Hospital, Athens, Greece
[6] Department of Medical Oncology, 401 Military Hospital of Athens, Athens, Greece
[7] Second Department of Medical Oncology, Theagenion Anticancer Hospital of Thessaloniki, Thessaloniki, Greece
[8] Sotiria Chest Diseases Hospital, 8th Pulmonary Clinic, Athens, Greece
[9] Department of Pulmonary Diseases, Sismanoglion General Hospital of Athens, Athens, Greece
[10] Department of Internal Medicine, University General Hospital of Heraklion, University of Crete, Heraklion, Crete, Greece - Source
Cancer. 2013, Vol 119, Num 15, pp 2754-2764, 11 p ; ref : 32 ref
- CODEN
- CANCAR
- ISSN
- 0008-543X
- Scientific domain
- Medical oncology
- Publisher
- Wiley-Blackwell, Hoboken, NJ
- Publication country
- United States
- Document type
- Article
- Language
- English
- Author keyword
- EGFR mutation KRAS mutation erlotinib non-small cell lung cancer pemetrexed pretreated patients
- Keyword (fr)
- Anticancéreux Cancer du poumon Cancérologie Carcinome non petite cellule bronchopulmonaire Erlotinib Essai clinique phase III Etude comparative Gène K ras Gène onc cellulaire Génétique Homme Mutation Protooncogène Pémétrexed Randomisation Recherche Récepteur facteur croissance épiderme Stade avancé Tumeur maligne Anti-EGFR Inhibiteur de la tyrosine kinase de l'EGFR Antifolate Cancer Dérivé de la quinazoline Enzyme Inhibiteur de la tyrosine kinase Inhibiteur enzyme Pathologie de l'appareil respiratoire Pathologie des bronches Pathologie des poumons Protein-tyrosine kinase Transferases
- Keyword (en)
- Antineoplastic agent Lung cancer Cancerology non-small cell lung carcinoma Erlotinib Phase III trial Comparative study K ras Gene C-Onc gene Genetics Human Mutation Protooncogene Pemetrexed Randomization Research Epidermal growth factor receptor Advanced stage Malignant tumor Antifolate Cancer Quinazoline derivatives Enzyme Tyrosine kinase inhibitor Enzyme inhibitor Respiratory disease Bronchus disease Lung disease Protein-tyrosine kinase Transferases
- Keyword (es)
- Anticanceroso Cáncer del pulmón Cancerología Carcinoma no pequeňa célula bronchopulmonar Erlotinib Ensayo clínico fase III Estudio comparativo Gen K ras Gen onc celular Genética Hombre Mutación Protooncogen Pemetrexed Aleatorización Investigación Receptor del factor de crecimiento epidérmico Estadio avanzado Tumor maligno Antifolato Cáncer Enzima Inhibidor tyrosine kinase Inhibidor enzima Aparato respiratorio patología Bronquio patología Pulmón patología Protein-tyrosine kinase Transferases
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B04 Tumors / 002B04C Multiple tumors. Solid tumors. Tumors in childhood (general aspects)
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B11 Pneumology / 002B11A Tumors of the respiratory system and mediastinum
- Discipline
- Pulmonology Tumours
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 27569194
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1002/cncr.28132 
https://dx.doi.org/10.1002/cncr.28132
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.28132\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:159:\"Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study\";s:9:\"\u0000*\u0000jtitle\";s:6:\"Cancer\";s:9:\"\u0000*\u0000stitle\";s:6:\"Cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"119\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"2754\";s:8:\"\u0000*\u0000epage\";s:4:\"2764\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-543X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"KARAMPEAZIS\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Athanasios\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:19:\"VOUTSINA, Alexandra\";i:1;s:14:\"AGELAKI, Sofia\";i:2;s:17:\"VAMVAKAS, Lambros\";i:3;s:15:\"SAMONIS, George\";i:4;s:19:\"MAVROUDIS, Dimitris\";i:5;s:21:\"GEORGOULIAS, Vassilis\";i:6;s:15:\"SOUGLAKOS, John\";i:7;s:19:\"KENTEPOZIDIS, Nikos\";i:8;s:16:\"GIASSAS, Stelios\";i:9;s:28:\"CHRISTOFILLAKIS, Charalambos\";i:10;s:20:\"KOTSAKIS, Athanasios\";i:11;s:20:\"PAPAKOTOULAS, Pavlos\";i:12;s:14:\"RAPTI, Ageliki\";i:13;s:15:\"AGELIDOU, Maria\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CANCAR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:159:\"Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Wiley-Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.28132\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:159:\"Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study\";s:9:\"\u0000*\u0000jtitle\";s:6:\"Cancer\";s:9:\"\u0000*\u0000stitle\";s:6:\"Cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"119\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"2754\";s:8:\"\u0000*\u0000epage\";s:4:\"2764\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-543X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"KARAMPEAZIS\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Athanasios\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:19:\"VOUTSINA, Alexandra\";i:1;s:14:\"AGELAKI, Sofia\";i:2;s:17:\"VAMVAKAS, Lambros\";i:3;s:15:\"SAMONIS, George\";i:4;s:19:\"MAVROUDIS, Dimitris\";i:5;s:21:\"GEORGOULIAS, Vassilis\";i:6;s:15:\"SOUGLAKOS, John\";i:7;s:19:\"KENTEPOZIDIS, Nikos\";i:8;s:16:\"GIASSAS, Stelios\";i:9;s:28:\"CHRISTOFILLAKIS, Charalambos\";i:10;s:20:\"KOTSAKIS, Athanasios\";i:11;s:20:\"PAPAKOTOULAS, Pavlos\";i:12;s:14:\"RAPTI, Ageliki\";i:13;s:15:\"AGELIDOU, Maria\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CANCAR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:159:\"Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Wiley-Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.28132\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.28132\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:159:\"Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study\";s:9:\"\u0000*\u0000jtitle\";s:6:\"Cancer\";s:9:\"\u0000*\u0000stitle\";s:6:\"Cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"119\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"2754\";s:8:\"\u0000*\u0000epage\";s:4:\"2764\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-543X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"KARAMPEAZIS\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Athanasios\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:19:\"VOUTSINA, Alexandra\";i:1;s:14:\"AGELAKI, Sofia\";i:2;s:17:\"VAMVAKAS, Lambros\";i:3;s:15:\"SAMONIS, George\";i:4;s:19:\"MAVROUDIS, Dimitris\";i:5;s:21:\"GEORGOULIAS, Vassilis\";i:6;s:15:\"SOUGLAKOS, John\";i:7;s:19:\"KENTEPOZIDIS, Nikos\";i:8;s:16:\"GIASSAS, Stelios\";i:9;s:28:\"CHRISTOFILLAKIS, Charalambos\";i:10;s:20:\"KOTSAKIS, Athanasios\";i:11;s:20:\"PAPAKOTOULAS, Pavlos\";i:12;s:14:\"RAPTI, Ageliki\";i:13;s:15:\"AGELIDOU, Maria\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CANCAR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:159:\"Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Wiley-Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.28132\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:159:\"Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study\";s:9:\"\u0000*\u0000jtitle\";s:6:\"Cancer\";s:9:\"\u0000*\u0000stitle\";s:6:\"Cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"119\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"2754\";s:8:\"\u0000*\u0000epage\";s:4:\"2764\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-543X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"KARAMPEAZIS\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Athanasios\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:19:\"VOUTSINA, Alexandra\";i:1;s:14:\"AGELAKI, Sofia\";i:2;s:17:\"VAMVAKAS, Lambros\";i:3;s:15:\"SAMONIS, George\";i:4;s:19:\"MAVROUDIS, Dimitris\";i:5;s:21:\"GEORGOULIAS, Vassilis\";i:6;s:15:\"SOUGLAKOS, John\";i:7;s:19:\"KENTEPOZIDIS, Nikos\";i:8;s:16:\"GIASSAS, Stelios\";i:9;s:28:\"CHRISTOFILLAKIS, Charalambos\";i:10;s:20:\"KOTSAKIS, Athanasios\";i:11;s:20:\"PAPAKOTOULAS, Pavlos\";i:12;s:14:\"RAPTI, Ageliki\";i:13;s:15:\"AGELIDOU, Maria\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CANCAR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:159:\"Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Wiley-Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:7:\"journal\";s:6:\"\u0000*\u0000doi\";s:18:\"10.1002\/cncr.28132\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:159:\"Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study\";s:9:\"\u0000*\u0000jtitle\";s:6:\"Cancer\";s:9:\"\u0000*\u0000stitle\";s:6:\"Cancer\";s:7:\"\u0000*\u0000date\";s:4:\"2013\";s:9:\"\u0000*\u0000volume\";s:3:\"119\";s:8:\"\u0000*\u0000issue\";s:2:\"15\";s:8:\"\u0000*\u0000spage\";s:4:\"2754\";s:8:\"\u0000*\u0000epage\";s:4:\"2764\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0008-543X\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:11:\"KARAMPEAZIS\";s:10:\"\u0000*\u0000aufirst\";s:10:\"Athanasios\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:14:{i:0;s:19:\"VOUTSINA, Alexandra\";i:1;s:14:\"AGELAKI, Sofia\";i:2;s:17:\"VAMVAKAS, Lambros\";i:3;s:15:\"SAMONIS, George\";i:4;s:19:\"MAVROUDIS, Dimitris\";i:5;s:21:\"GEORGOULIAS, Vassilis\";i:6;s:15:\"SOUGLAKOS, John\";i:7;s:19:\"KENTEPOZIDIS, Nikos\";i:8;s:16:\"GIASSAS, Stelios\";i:9;s:28:\"CHRISTOFILLAKIS, Charalambos\";i:10;s:20:\"KOTSAKIS, Athanasios\";i:11;s:20:\"PAPAKOTOULAS, Pavlos\";i:12;s:14:\"RAPTI, Ageliki\";i:13;s:15:\"AGELIDOU, Maria\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"CANCAR\";s:8:\"\u0000*\u0000genre\";s:7:\"article\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:0:\"\";s:8:\"\u0000*\u0000title\";s:159:\"Pemetrexed Versus Erlotinib in Pretreated Patients With Advanced Non-Small Cell Lung Cancer: A Hellenic Oncology Research Group (HORG) Randomized Phase 3 Study\";s:8:\"\u0000*\u0000place\";s:11:\"Hoboken, NJ\";s:6:\"\u0000*\u0000pub\";s:15:\"Wiley-Blackwell\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"11\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
